Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein A-I is protective for the incidence of primary acute myocardial infarction in middle-aged males. An incident case-control study from Sweden

Journal of Internal Medicine

Volumn 244, Issue 5, 1998, Pages 425-430

  Dahlen G H ^a   Weinehall, L ^a   Stenlund, H ^a   Jansson, J H ^a   Hallmans, G ^a   Huhtasaari, F ^a   Wall, S ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Acute myocardial infarction; Case control study; Lipids; Lipoprotein(a); Lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; LIPOPROTEIN A;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SWEDEN;

EID: 0031791037     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1998.00422.x     Document Type: Article

References (24)

1. Barr DP, Russ EM, Eder HA. Protein-lipid relationships in human plasma. Am J Med 1951; 11: 480-93.
2. Gofman JW, Hanig M, Jones HB, Lauffer MA, Lawry EY, Lewis LA et al. Evaluation of scrum lipoprotein and cholesterol measurements as predictors of clinical, complications of atherosclerosis, Circulation 1956; 14: 691-741.
3. Miller GJ, Miller NK. Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet 1975; 1: 16-9.
4. Berg K, Borresen A-L, Dahlén GH. Serum-high-density-lipoprotein and atherosclerotic heart-disease. Lancet 1976; 6: 499-501.
5. Dahlén GH. Lp (a) lipoprotein in cardiovascular disease. Review article and viewpoint. Atherosclerosis 1994; 108: 111-26.
6. Dahlén GH, Berg K, Ramberg U-B, Tamm A. Lp (a) lipoprotein and pre-beta-1-lipoprotein in young adults. Acta Med Scand 1974; 196: 327-31.
7. Dahlén GH, Ericson C, Furberg C. Myocardial infarction and an extra pre-beta lipoprotein fraction. Acta Med Scand Supplement 1972; 531: 25-9.
8. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE et al. Lipoprotein (a) levels and risk of coronary heart disease in men. JAMA 1994; 271: 999-1003.
9. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PW et al. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. JAMA 1996; 276: 544-8.
10. Dahlén GH. Incidence of Lp (a) lipoprotein among populations. In: Scanu AM, ed. Lipopratein (a). San Diego: Academic Press, 1990; 151-73.
11. Dahlén GH. Lipoprotein (a) as a risk factor for atherosclerotic diseases. Arctic Med Res 1988; 47: 458-61.
12. Lenner P, Hallmans G, Weinehall L, Stenling R. Population-based biological test bank. New possibilities for epidemiologic cancer research. Läkartidningen 1991; 88: 4447-9 (in Swedish).
13. Huhtasaari F, Asplund K, Wester PO. Cardiovascular risk factors in the Northern Sweden MONICA Study. Acta Med Scand 1988; 224: 99-108.
14. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Rajakangas AM, Pajak A. Myocardial infarction and coronary death in the World Health Organisation MONICA project. Circulation 1994; 90: 583-612.
15. von Schenck H, Treichl L, Tilling B, Olsson AG. Laboratory and field evaluation of three desk top instruments for blood cholesterol and triglyceride assay. Clin Chem 1987; 33: 1230-2.
16. Heller DA, de Faire U, Pedersen NL, Dahlén GH, McClearn GE. Genetic and environmental influences on serum lipid levels in twins. N Engl J Med 1993; 328: 1150-6.
17. Checkoway H, Hickey JLS. Estimating the potential disease rale reduction under varying conditions of combined effects. J Epidemiol 1988; 17: 666-72.
18. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a). JAMA 1995; 274: 1771-4.
19. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987; 330: 132-7.
20. Wållberg-Jonsson S, Dahlén GH, Nilsson TK, Ranby M, Rantapää-Dahlqvist S. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin Rheumatol 1993; 12: 318-24.
21. Moliterno DJ, Lange RA, Meidell RS, Willard JE, Leffert CC, Gerard RD et al. Relation of plasma lipoprotein (a) to infarct artery patency in survivors of myocardial infarction. Circulation 1993; 88: 935-40.
22. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl Med 1992; 326: 242-50.
23. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
24. Pedersen TR. Lowering cholesterol with drugs and diets. N Engl J Med 1995; 333: 1351-2.